The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study

Mulder, Hans; Franke, Barbara; der, A Aart van der – Beek van; Arends, Johan; Wilmink, Frederik W.; Egberts, Toine C. G.; Scheffer, Hans

doi:10.1038/sj.tpj.6500422

Cited by 45 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From a total of 27 potentially eligible studies, 7 were excluded because they are not relevant to the study question (Bai et al 2011;Houston et al 2012), or review articles (Gentile 2006;Reynolds et al 2006;Arranz et al 2011;Lett et al 2012) or meeting abstract (Ujike et al 2008b). From the 20 studies assessed in detail, 1 was excluded because no information about the HTR2C -759 C/T genotype or allelic frequencies was given (Gunes et al 2009), 2 were excluded because no detailed number of the patients having high weight gain and low weight was given (Ujike et al 2008a;Laika et al 2010), 7 were excluded because multiple types of SGAs were used to assess the SGA-induced weight gain without being broken down into separate groups with detailed numbers of the patients with high or low weight gain (Reynolds et al 2002;Templeman et al 2005;Mulder et al 2007b;Ryu et al 2007;Opgen-Rhein et al 2010;Sicard et al 2010;Gregoor et al 2011). A total of 10 studies were included in the current meta-analyses and their data were extracted; among them, 4 were included in the meta-analysis of the HTR2C -759C/T polymorphism and olanzapine-induced weight gain Kuzman et al 2008;Park et al 2008;Godlewska et al 2009), 6 were included in the meta-analysis of the HTR2C -759C/T polymorphism and olanzapine/clozapine/risperidone-induced metabolic syndrome (Yevtushenko et al 2008;Kuzman et al 2011;Mulder et al 2007aMulder et al , 2009Kang et al 2011;Risselada et al 2012); among the later 6, 3 were further included in the meta-analysis of the HTR2C -697G/C polymorphism and olanzapine/clozapine/risperidone-induced metabolic Total potentially eligible studies, N=27 Studies excluded through screening:…”

Section: Resultsmentioning

confidence: 99%

HTR2Cpolymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

Maimaitirexiati

Zeng

et al. 2014

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

HTR2Cpolymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

Maimaitirexiati

Zeng

et al. 2014

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

show abstract

“…This SNP was included in the study because it showed the strongest association with obesity in an earlier study performed in the same test population. 10,11 The genotyping methods are described in our earlier publications. 9,11 Data Analysis…”

Section: Determinantsmentioning

confidence: 99%

Combined HTR2C-LEP Genotype as a Determinant of Obesity in Patients Using Antipsychotic Medication

Gregoor¹,

Mulder²,

Cohen³

et al. 2010

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Obesity is one of the most serious common somatic adverse effects of atypical antipsychotic agents. Genetic factors partly determine the individual patients risk of developing obesity during treatment. As weight-regulating mechanisms, such as the leptinergic and serotonergic system, may be interdependent, genetic polymorphisms in these systems also may show interactions. To determine whether combined HTR2CLEP genotype or HTR2C-LEPR genotype are associated with obesity in patients using atypical antipsychotic drugs, a cross-sectional study design was used. The study population included 200 patients aged between 18 and 65 years of age, diagnosed with a psychotic disorder, all of whom had been using an atypical antipsychotic for at least 3 months. Primary outcome measure was presence of obesity (body mass index, >30). Determinants were the combined (HTR2C -759C/T-LEPR Q223R), (HTR2C -759C/T-LEP -2548G/A, (HTR2C rs1414334-LEPR Q223R) and (HTR2C rs1414334-LEP -2548G/A) genotypes. Of the 200 included patients, 61 (31%) were obese. In patients without the HTR2C -759T allele, presence of the LEP -2548G allele was associated with obesity (odds ratio, 2.88; 95% confidence interval, 1.05-7.95). The results of the other analyses showed some nonsignificant trends. The combined (HTR2C -759C/TYLEP -2548G/A) genotype may be a determinant of obesity in patients during treatment with atypical antipsychotic drugs.

show abstract

“…From a pharmacological point of view, inhibition of the NE reuptake transporter increases synaptic NE disposal directly by stimulating glycogenolysis and gluconeogenesis, resulting in raised blood glucose levels [22]. It is also postulated that central blockade of the H 1 receptor and 5-HT 2c receptor stimulates energy intake by increasing appetite with a resultant positive energy balance, thereby causing weight gain [23][24][25]. Weight gain may result in insulin resistance and increase the risk of hyperglycaemia.…”

Section: Hyperglycaemiamentioning

confidence: 99%

The Association between Antidepressant Use and Disturbances in Glucose Homeostasis: Evidence from Spontaneous Reports

et al. 2007

View full text Add to dashboard Cite

Objectives Depression is common in patients with diabetes, and the use of antidepressants may impair glycaemic control. We assessed the association between antidepressant use and hyper-and hypoglycaemia. Methods Based on spontaneous reports listed in the World Health Organization (WHO) Adverse Drug Reaction Database, a case-control study was conducted. The study base consisted of all adverse drug reactions (ADRs) ascribed to antidepressants, antipsychotics and benzodiazepines between 1969 and 2005. Cases were defined as reported ADRs classified as hyper-or hypoglycaemia and separated in different study populations. All other reports were considered as controls. Exposure to antidepressants was the primary determinant investigated. Benzodiazepines and antipsychotics were chosen as reference groups. Potential confounding factors, namely, age, gender, use of antidiabetic medication, use of hyper-or hypoglycaemiainducing comedication and reporting year, were determined on the index date. Multivariate logistic regression was used to evaluate the strength of the association, which was expressed as reporting odds ratios (RORs) with 95% confidence intervals (95% CI). Results Overall, the use of antidepressants was associated with hyperglycaemia [ROR 1.52 (95% CI: 1.20-1.93)] and of hypoglycaemia [ROR 1.84 (95% CI: 1.40-2.42)]. The association with hyperglycaemia was most pronounced for antidepressants with affinity for the 5-HT 2c receptor, histamine-1 receptor and norepinephrinic (NE) reuptake transporter. The association with hypoglycaemia was most pronounced for antidepressants with affinity for the serotonin reuptake transporter. Conclusion The results of this study strengthen the findings in individual case reports that the use of antidepressants is associated with disturbances in glucose homeostasis.

show abstract

The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study

Cited by 45 publications

References 24 publications

HTR2Cpolymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

HTR2Cpolymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

Combined HTR2C-LEP Genotype as a Determinant of Obesity in Patients Using Antipsychotic Medication

The Association between Antidepressant Use and Disturbances in Glucose Homeostasis: Evidence from Spontaneous Reports

Contact Info

Product

Resources

About